Cyclin-Dependent Kinase 9 (CDK9) Inhibitor Pipeline Research Report 2024: Drugs in Development, Therapeutics Scenario and Growth Prospects Dublin, April 15, 2024 (GLOBE NEWSWIRE) -- The "Cyclin-Dependent Kinase 9 (CDK9) Inhibitor - Pipeline Insight, 2024" clinical trials has been added to ResearchAndMarkets.com's...

CDK9 inhibitor Drug Pipeline Research Report 2024 Dublin, April 12, 2024 (GLOBE NEWSWIRE) -- The "CDK9 inhibitor - Pipeline Insight, 2024" drug pipelines has been added to ResearchAndMarkets.com's offering."Cyclin-Dependent Kinase 9 (CDK9)...

Cyclacel Pharmaceuticals to Present New Clinical Data at 2024 ASCO Annual Meeting Highlighting Fadraciclib’s Potential as a Precision Medicine for Cancer - New clinical, PK and PD data from novel CDK2/9 inhibitor fadraciclib monotherapy studies support ongoing development program in patients with solid tumors and lymphoma - BERKELEY HEIGHTS, N.J.,...